Goldman Sachs Downgrades Biogen (BIIB) to Neutral, Removes from CL List

May 1, 2013 7:20 AM EDT Send to a Friend
Get Alerts BIIB Hot Sheet
Price: $335.45 -0.4%

Rating Summary:
    21 Buy, 7 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 38 | New: 6
Trade BIIB Now!
Join SI Premium – FREE
Goldman Sachs downgraded Biogen (NASDAQ: BIIB) from Conviction Buy to Neutral with a price target of $215.00 (from $211.00), saying they prefer Amgen (NASDAQ: AMGN) which was added upgraded and added to the Conviction Buy List.

"We continue to view BIIB as a solid growth story within large-cap biotech, driven by what is proving to be a strong launch of new oral multiple sclerosis (MS) drug Tecfidera. However, we now see risk/reward as balanced," analyst Terence Flynn said.

While downgrading, Goldman raised FY 2013 EPS estimates on Biogen from $7.77 to $8.09, raised FY 2014 EPS from $10.39 to $10.43 and FY 2015 was trimmed from $13.33 to $13.24.

For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.

Shares of Biogen closed at $218.93 yesterday.




You May Also Be Interested In


Related Categories

Analyst EPS Change, Analyst PT Change, Downgrades, Hot Downgrades

Related Entities

Goldman Sachs Conviction Buy List, Goldman Sachs

Add Your Comment